Radiofrequency catheter ablation (RFCA) has been considered the first-line therapy for treatment of drug-refractory ventricular arrhythmias (VAs).1 The success of catheter ablation depends on our ability to reach the anatomic location of the ventricular tachycardia (VT) substrate. VTs arising from deep intramural regions2 or in close proximity to coronary vessels3 can have limited RFCA success. Transarterial coronary ethanol ablation has been used as an alternative treatment option and is reasonably successful in treating RFCA-refractory VTs.
Radiofrequency catheter ablation (RFCA) has been considered the first-line therapy for treatment of drug-refractory ventricular arrhythmias (VAs).1 The success of catheter ablation depends on our ability to reach the anatomic location of the ventricular tachycardia (VT) substrate. VTs arising from deep intramural regions2 or in close proximity to coronary vessels3 can have limited RFCA success. Transarterial coronary ethanol ablation has been used as an alternative treatment option and is reasonably successful in treating RFCA-refractory VTs.